Issue 9, 2009
From the journal:

Journal of Analytical Atomic Spectrometry

Determination of metal residues in active pharmaceutical ingredients according to European current legislation by using X-ray fluorescence spectrometry

E. Marguí,*a   C. Fontàs,b   A. Buendía,c   M. Hidalgob  and  I. Queralta  

* Corresponding authors

a Laboratory of X-Ray Analytical Applications, Institute of Earth Sciences “Jaume Almera”, CSIC, Solé Sabarís s/n, Barcelona, Spain
E-mail: emargui@ija.csic.es
Fax: (+34) 934110012
Tel: (+34) 934095410

b Department of Chemistry, University of Girona, Campus Montilivi, Girona, Spain

c Department of Quality Control, Medichem, S.A. Pol.Ind.Celrà, Celrà, Spain

Abstract

The monitoring of heavy metals in drug substances is an important task in modern pharmaceutical laboratories. In the present work, a rapid and simple method for the determination of some inorganic impurities (Fe, Zn, Cr and Ni) in active pharmaceutical ingredients (APIs) by wavelength dispersive X-ray fluorescence spectrometry (WDXRF) has been developed and validated according to the specification limits of the European Agency for the Evaluation of Medicinal Products (EMEA) and the guidelines of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use (ICH). The achieved results showed that the API's matrix significantly affects the determination of metals by XRF spectrometry and this fact has to be taken into consideration when selecting the best compound candidate to prepare the synthetic calibration standards for quantitation purposes. The calculated LODs and LOQs meet the rigorous limit requirements of current legislation and, hence, the use of this analytical technique is presented as an interesting alternative to the current compendial “heavy metal test” that is going to be replaced with an instrument-based approach by international pharmacopoeias in the near future.

Graphical abstract: Determination of metal residues in active pharmaceutical ingredients according to European current legislation by using X-ray fluorescence spectrometry

About
Cited by
Related
Download options Please wait...

Article information

DOI
https://doi.org/10.1039/B904064A
Article type
Technical Note
Submitted
26 Feb 2009
Accepted
01 Jun 2009
First published
16 Jun 2009

J. Anal. At. Spectrom., 2009,24, 1253-1257

Permissions

Request permissions

Determination of metal residues in active pharmaceutical ingredients according to European current legislation by using X-ray fluorescence spectrometry

E. Marguí, C. Fontàs, A. Buendía, M. Hidalgo and I. Queralt, J. Anal. At. Spectrom., 2009, 24, 1253 DOI: 10.1039/B904064A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements